Protective Effect of Silibinin on Lipopolysaccharide-Induced Inflammatory Responses in Equine Peripheral Blood Mononuclear Cells, an In Vitro Study.
Authors: Gugliandolo Enrico, Crupi Rosalia, Biondi Vito, Licata Patrizia, Cuzzocrea Salvatore, Passantino Annamaria
Journal: Animals : an open access journal from MDPI
Summary
Bacterial lipopolysaccharide (LPS) triggers potent inflammatory cascades in equine immune cells that contribute significantly to conditions ranging from sepsis to colitis, yet therapeutic options for moderating these responses remain limited. Gugliandolo and colleagues employed an in vitro model using equine peripheral blood mononuclear cells exposed to LPS, then treated with silibinin—a polyphenolic flavonoid from milk thistle—at concentrations of 10 and 50 µM to assess its immunomodulatory capacity. Silibinin demonstrated dose-dependent suppression of pro-inflammatory cytokine production, substantially reducing LPS-induced elevations in TNF-α, IL-1β, IL-6, and IL-8 compared to untreated controls. Whilst these findings are promising for future therapeutic applications in managing endotoxaemia and inflammatory disease in horses, the in vitro setting means direct translation to clinical efficacy and appropriate dosing in vivo requires further investigation through equine models and clinical trials. For practitioners, this research provides a biochemical rationale for exploring milk thistle supplementation as an adjunctive anti-inflammatory strategy, though evidence-based dosing protocols and safety profiles in living horses remain to be established.
Read the full abstract on PubMed
Practical Takeaways
- •Silibinin may represent a novel therapeutic approach for managing inflammatory conditions in horses secondary to bacterial infection or endotoxemia, though clinical studies are needed
- •This in vitro research suggests milk thistle-derived compounds warrant further investigation as potential adjunctive treatments for equine systemic inflammatory conditions
- •Current evidence is limited to cell culture; clinical efficacy, dosing, and safety profile in live horses remain to be established
Key Findings
- •Silibinin at 10 µM and 50 µM concentrations protected equine PBMCs against LPS-induced inflammatory response
- •Silibinin prevented LPS-induced increases in TNF-α, IL-1β, IL-6, and IL-8 cytokine levels
- •Natural polyphenolic flavonoid silibinin demonstrated antioxidant, immunomodulatory, and anti-inflammatory properties in equine cells